Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

±¸°­°ÇÁ¶Áõ¿¡ ´ëÇÑ ÇÊ·ÎÄ«ÇÉ ±¸°­¾çÄ¡¾×ÀÇ È¿°ú

Effect of Pilocarpine Mouthwash on Xerostomia

´ëÇѱ¸°­³»°úÇÐȸÁö 2011³â 36±Ç 1È£ p.21 ~ 24
±èÁöÇö, ¹ÚÁÖÇö, ±ÇÁ¤½Â, ¾ÈÇüÁØ,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÁöÇö ( Kim Ji-Hyun ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç
¹ÚÁÖÇö ( Park Ju-Hyun ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç
±ÇÁ¤½Â ( Kwon Jeong-Seung ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç
¾ÈÇüÁØ ( Ahn Hyung-Joon ) - ¿¬¼¼´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç

Abstract

±¸°­°ÇÁ¶ÁõÀ̶õ ÁÖ°üÀûÀÎ ±¸°­ ³» °ÇÁ¶°¨À¸·Î Á¤ÀǵǸç, ÀÌ´Â ¾à¹°, Ÿ¾×¼± Áúȯ, ¹æ»ç¼± Ä¡·á, ½¦±×·» ÁõÈıº, ½É¸®Àû ¿äÀÎ µî°ú °°Àº ´Ù¾çÇÑ ¿øÀο¡¼­ ºñ·ÔµÈ´Ù.
±¸°­ °ÇÁ¶Áõ ȯÀÚ Áß ÇöÀúÇÑ Å¸¾×¼± ±â´É °¨¼Ò°¡ Á¸ÀçÇÏ´Â °æ¿ì ±¸°­Äµµð´ÙÁõ, Ä¡¾Æ¿ì½ÄÁõ, Ä¡ÁÖÁúȯ, ¹Ì°¢º¯È­, ±¸Ãë µîÀÇ º´¹ßÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ ±¸°­°ÇÁ¶ÁõÀÇ Ä¡·á·Î´Â ¿ì¼±ÀûÀ¸·Î ±¸°­°ÇÁ¶¸¦ À¯¹ßÇÏ´Â ¿øÀοä¼Ò¸¦ Á¦°ÅÇϰųª, ȯÀÚÀÇ ºÒÆí°¨À» °¨¼Ò½ÃÅ°±â À§ÇÑ ´ëÁõ¿ä¹ýÀÌ ÁÖ°¡ µÇ¸ç ½ÇÁ¦·Î Ÿ¾× ºÐºñ ±â´ÉÀÌ °¨¼ÒµÈ °æ¿ì ÀÌ·Î ÀÎÇÑ ÇÕº´ÁõÀ» ¿¹¹æÇϱâ À§ÇÑ Ä¡·á¿Í Ÿ¾×ºÐºñ¸¦ ÀÚ±ØÇÒ ¼ö ÀÖ´Â ¾à¹°Ä¡·á¸¦ ½ÃÇàÇÒ ¼ö ÀÖ´Ù.
ÀÌ Áß Å¸¾×ºÐºñ¸¦ ÃËÁø½ÃÅ°´Â ¾à¹°ÀÎ ÇÊ·ÎÄ«ÇÉÀº ±¸°­°ÇÁ¶Áõ Ä¡·áÁ¦·Î ³Î¸® »ç¿ëµÇ¾î ¿Ô´Ù. ÇÏÁö¸¸ ¹ßÇÑÀÛ¿ë, ºñ´¢±â ¹× À§Àå°ü°èÀÇ ºñÁ¤»óÀûÀÎ ±â´ÉÀ¯µµ, ½ÉÇ÷°ü°è ¹× È£Èí±â°è¿¡ ´ëÇÑ À§Çè µîÀÇ ºÎÀÛ¿ëÀÌ ÀÖ¾î õ½Ä, ¸¸¼ºÆóÁúȯ, ½ÉÇ÷°ü°è ÁúȯÀÚ¿¡°Ô´Â ÁÖÀÇ ±íÀº »ç¿ëÀÌ ¿ä±¸µÇ¸ç, ƯÈ÷ Á¶ÀýµÇÁö ¾Ê´Â õ½ÄȯÀÚÀÇ °æ¿ì ÇÊ·ÎÄ«ÇÉÀÇ Àý´ëÀû ±Ý±âÁõÀ¸·Î »ç¿ëÀÌ ±ÝÁöµÈ´Ù. ÀÌó·³ ±¸°­°ÇÁ¶Áõ Ä¡·á¿¡ ÀÖ¾î ÇÊ·ÎÄ«ÇÉÀº ºÎÀÛ¿ëÀ¸·Î ÀÎÇØ Àü½ÅÀûÀÎ Åõ¿©¿¡ ¸¹Àº Á¦ÇÑÀÌ ÀÖ´Ù.
µû¶ó¼­, ÇÊ·ÎÄ«ÇÉÀÇ ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ±¹¼ÒÀûÀ¸·Î »ç¿ëµÇ´Â ¹æ¹ý ÁßÀÇ ÇϳªÀÎ ÇÊ·ÎÄ«ÇÉ ¾çÄ¡¾×À» ÀÌ¿ëÇÏ¿© Ä¡·áÇÑ Áõ·Ê¸¦ ÅëÇØ ±× È¿°ú¸¦ È®ÀÎÇغ¸°íÀÚ ÇÏ¿´´Ù.

Xerostomia is subjective feeling of dry mouth, a symptom that may or may not be accompanied by hyposalivation, an objective decrease in salivary flow. There are many causes induced xerostomia like drugs, salivary gland diseases, radiation therapy to the head and neck region, Sjogren syndrome, emotional stress etc. Insufficient salivary flow creates complications with oral candidiasis, dental caries, periodontitis, halitosis, dysgeusia. So finally, these complications lead to an overall decline in quality of life.
Managements of xerostomia are eliminating or alterating the etiologic factors, relieving symptoms, preventing or correcting the consequences of salivary dysfunction, treating underlying disease and stimulating salivation. One of the salivation stimulation agents studied to treat xerostomia was the pilocarpine muscarinic agonist. Pilocarpine is one of salivation stimulants, a parasympathomimetic drug and non-selective muscarinic receptor agonist. Systemic pilocarpine has been used to stimulate salivary secretion. But systemic administration of pilocarpine has limitations such as increased risk of side effects and contraindications. Side effects of systemic pilocarpine administration are sweating, urinary and gastrointestinal disturbance, risk of cardiovascular and pulmonary disorders. This drug must be used carefully by patients with controlled asthma, chronic bronchitis, pulmonary or cardiac disease. Patient with acute asthma, narrow angle glaucoma, iritis should not use pilocarpine. Like this, systemic pilocarpine has many limitations.
So, many investigators also have looked at the effectiveness of topical pilocarpine. Here we present patients with xerostomia which was relieved by pilocarpine mouthwash.

Å°¿öµå

±¸°­°ÇÁ¶Áõ; ÇÊ·ÎÄ«ÇÉ ¾çÄ¡¾×
Pilocarpine mouthwash; Xerostomia

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI